Roivant Sciences Ltd. Common Shares (ROIV) is a publicly traded Healthcare sector company. As of May 20, 2026, ROIV trades at $32.12 with a market cap of $20.43B and a P/E ratio of -118.03. ROIV moved +13.86% today. Year to date, ROIV is +28.64%; over the trailing twelve months it is +160.24%. Its 52-week range spans $8.73 to $30.33. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces ROIV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ROIV financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ROIV recently traded at $32.12. Market cap is $20.43B. P/E ratio is -118.03. Revenue is $29.05M.
| Metric | Value |
|---|---|
| Price | $32.12 |
| Market Cap | $20.43B |
| P/E Ratio | -118.03 |
| EPS | $-0.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.33 |
| 52-Week Low | $8.73 |
| Volume | 7.05M |
| Avg Volume | 0 |
| Revenue (TTM) | $29.05M |
| Net Income | $-356.73M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $29.05M | $-356.73M | $-0.24 |
| 2023 | $61.28M | $-1.12B | $-1.42 |
| 2022 | $55.29M | $-924.12M | $0.00 |
8 analysts cover ROIV: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.